Unknown

Dataset Information

0

Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis.


ABSTRACT: INTRODUCTION:Long-term outcome data provide important insights into the clinical utility of enzyme replacement therapies. Such data are presented for velmanase alfa in the treatment of alpha-mannosidosis (AM). METHODS:Patient data (n?=?33; 14 adults, 19 paediatric) from the clinical development programme for velmanase alfa were integrated in this prospectively-designed analysis of long-term efficacy and safety. Patients who participated in the phase I/II or phase III trials and were continuing to receive treatment after completion of the trials were invited to participate in a comprehensive evaluation visit to assess long-term outcomes. Primary endpoints were changes in serum oligosaccharide and the 3-minute stair climb test (3MSCT). RESULTS:Mean (SD) treatment exposure was 29.3 (15.2) months. Serum oligosaccharide levels were significantly reduced in the overall population at 12 months (mean change: -72.7%, P?

SUBMITTER: Lund AM 

PROVIDER: S-EPMC6326957 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Introduction</h4>Long-term outcome data provide important insights into the clinical utility of enzyme replacement therapies. Such data are presented for velmanase alfa in the treatment of alpha-mannosidosis (AM).<h4>Methods</h4>Patient data (n = 33; 14 adults, 19 paediatric) from the clinical development programme for velmanase alfa were integrated in this prospectively-designed analysis of long-term efficacy and safety. Patients who participated in the phase I/II or phase III trials and we  ...[more]

Similar Datasets

| S-EPMC1133862 | biostudies-literature
| S-EPMC9421599 | biostudies-literature
| S-EPMC10702697 | biostudies-literature
| S-EPMC1186164 | biostudies-other
| S-EPMC3755547 | biostudies-literature
| S-EPMC2515294 | biostudies-literature
| S-EPMC7463052 | biostudies-literature
| S-EPMC5074246 | biostudies-literature
| S-EPMC1163829 | biostudies-other
| S-EPMC6326984 | biostudies-literature